Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients
Future Oncology · 2024
DOI: 10.2217/fon-2023-0702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Ian Y Lee und 22 weiteren Autor:innen. Beteiligte Einrichtung: Henry Ford Health System, Detroit, MI 48202, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Drug Combinations. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Imvax, Inc..
Abstract (Originalsprache)
Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product of the Goldspire™ platform, is a first-in-class autologous immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers, with the intent to induce a tumor-specific immune response in patients with ndGBM. Here, we describe the design and rationale of a randomized, double-blind, phase IIb trial evaluating IGV-001 compared with placebo, both followed by standard-of-care treatment in patients with ndGBM. The primary end point is progression-free survival, and key secondary end points include overall survival and safety. Glioblastoma (GBM) is a fast-growing brain tumor that happens in about half of all gliomas. Surgery is the first treatment for patients with newly diagnosed GBM, followed by the usual radiation and chemotherapy pills named temozolomide. Temozolomide pills are then given as a long-term treatment. The outcome for the patient with newly diagnosed GBM remains poor. IGV-001 is specially made for each patient. The tumor cells are removed during surgery and mixed in the laboratory with a small DNA, IMV-001. This mix is the IGV-001 therapy that is designed to give antitumor immunity against GBM. IGV-001 is put into small biodiffusion chambers that are irradiated to stop the growth of any tumor cells in the chambers. In the phase IIb study, patients with newly diagnosed GBM are chosen and assigned to either the IGV-001 or the placebo group. A placebo does not contain any active ingredients. The small biodiffusion chambers containing either IGV-001 or placebo are surgically placed into the belly for 48 to 52 h and then removed. Patients then receive the usual radiation and chemotherapy treatment. Patients must be adults aged between 18 and 70 years. Patients also should be able to care for themselves overall, but may be unable to work or have lower ability to function. Patients with tumors on both sides of the brain are not eligible. The main point of this study is to see if IGV-001 helps patients live longer without making the illness worse compared with placebo. Clinical Trial Registration: NCT04485949 (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henry Ford Health System, Detroit, MI 48202, USA.
- Westchester Medical Center, Valhalla, NY 10595, USA.
- Northwell Health at North Shore University Hospital, Lake Success, NY 11030, USA.
- Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Rhode Island Hospital & The Warren Alpert Medical School of Brown University, Providence, RI 02912, USA.
- Ohio State University, Columbus, OH 43210, USA.
ORCID-Profile: Ian Y Lee, David W Andrews
Förderung
- Imvax, Inc.
Zitieren
APA
Lee, I. Y., Hanft, S., Schulder, M., Judy, K. D., Wong, E. T., Elder, J. B., Evans, L. T., Zuccarello, M., Wu, J., Aulakh, S., Agarwal, V., Ramakrishna, R., Gill, B. J., Quiñones-Hinojosa, A., Brennan, C., Zacharia, B. E., Silva Correia, C. E., Diwanji, M., Pennock, G. K., …, & Boockvar, J. A. (2024). Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients. Future Oncology. https://doi.org/10.2217/fon-2023-0702
Vancouver
Lee IY, Hanft S, Schulder M, Judy KD, Wong ET, Elder JB, et al. Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients. Future Oncology. 2024. doi:10.2217/fon-2023-0702
BibTeX
@article{Lee2024,
author = {Lee, Ian Y and Hanft, Simon and Schulder, Michael and Judy, Kevin D and Wong, Eric T and Elder, J Bradley and Evans, Linton T and Zuccarello, Mario and Wu, Julian and Aulakh, Sonikpreet and Agarwal, Vijay and Ramakrishna, Rohan and Gill, Brian J and Quiñones-Hinojosa, Alfredo and Brennan, Cameron and Zacharia, Brad E and Silva Correia, Carlos Eduardo and Diwanji, Madhavi and Pennock, Gregory K and Scott, Charles and Perez-Olle, Raul and Andrews, David W and Boockvar, John A},
title = {Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2023-0702}
}
EUVIMED